ARQT vs NVST
Arcutis Biotherapeutics, Inc. vs Envista Holdings — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
64
Buy
VS
NVST
Envista Holdings
76
Strong Buy
| Metric | ARQT | NVST |
|---|
| AI Score |
64
|
76
|
| Price |
$26.21
|
$28.51
|
| P/E Ratio |
118.80×
|
48.34×
|
| ROE |
-8.5%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
55.5%
|
| Debt / Equity |
0.52×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
44.7
|
59.3
|
| Beta |
1.526
|
0.861
|
| Expected Upside |
—
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus NVST.
NVST leads by 12 points.
NVST scores 76/100 (Strong Buy) versus ARQT at 64/100 (Buy).
ARQT Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.